Literature DB >> 7774020

Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes.

J Nasir1, S B Floresco, J R O'Kusky, V M Diewert, J M Richman, J Zeisler, A Borowski, J D Marth, A G Phillips, M R Hayden.   

Abstract

Huntington's disease (HD) is an incurable neuropsychiatric disease associated with CAG repeat expansion within a widely expressed gene that causes selective neuronal death. To understand its normal function, we have created a targeted disruption in exon 5 of Hdh (Hdhex5), the murine homolog of the HD gene. Homozygotes die before embryonic day 8.5, initiate gastrulation, but do not proceed to the formation of somites or to organogenesis. Mice heterozygous for the Hdhex5 mutation display increased motor activity and cognitive deficits. Neuropathological assessment of two heterozygous mice shows significant neuronal loss in the subthalamic nucleus. These studies show that the HD gene is essential for postimplantation development and that it may play an important role in normal functioning of the basal ganglia.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7774020     DOI: 10.1016/0092-8674(95)90542-1

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  250 in total

1.  Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease.

Authors:  J M Lecerf; T L Shirley; Q Zhu; A Kazantsev; P Amersdorfer; D E Housman; A Messer; J S Huston
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-10       Impact factor: 11.205

Review 2.  Transgenic models of Huntington's disease.

Authors:  K Sathasivam; C Hobbs; L Mangiarini; A Mahal; M Turmaine; P Doherty; S W Davies; G P Bates
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

3.  Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.

Authors:  P H Reddy; V Charles; M Williams; G Miller; W O Whetsell; D A Tagle
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

4.  An upstream open reading frame impedes translation of the huntingtin gene.

Authors:  Joseph Lee; Eun Hee Park; Graeme Couture; Isabelle Harvey; Philippe Garneau; Jerry Pelletier
Journal:  Nucleic Acids Res       Date:  2002-12-01       Impact factor: 16.971

5.  Wild-type HTT modulates the enzymatic activity of the neuronal palmitoyl transferase HIP14.

Authors:  Kun Huang; Shaun S Sanders; Rujun Kang; Jeffrey B Carroll; Liza Sutton; Junmei Wan; Roshni Singaraja; Fiona B Young; Lili Liu; Alaa El-Husseini; Nicholas G Davis; Michael R Hayden
Journal:  Hum Mol Genet       Date:  2011-06-02       Impact factor: 6.150

Review 6.  Intracellular inclusions, pathological markers in diseases caused by expanded polyglutamine tracts?

Authors:  D C Rubinsztein; A Wyttenbach; J Rankin
Journal:  J Med Genet       Date:  1999-04       Impact factor: 6.318

7.  Allele-specific silencing of dominant disease genes.

Authors:  Victor M Miller; Haibin Xia; Ginger L Marrs; Cynthia M Gouvion; Gloria Lee; Beverly L Davidson; Henry L Paulson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-02       Impact factor: 11.205

Review 8.  Huntington's disease: a decade beyond gene discovery.

Authors:  Penelope Hogarth
Journal:  Curr Neurol Neurosci Rep       Date:  2003-07       Impact factor: 5.081

Review 9.  Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.

Authors:  Ina Han; YiMei You; Jeffrey H Kordower; Scott T Brady; Gerardo A Morfini
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

Review 10.  Experimental surgical therapies for Huntington's disease.

Authors:  Jelle Demeestere; Wim Vandenberghe
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.